Liquidia Corporation (LQDA) Dividend History

Company News

• U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

  The U.S. FDA has approved Liquidia's YUTREPIA, an inhaled dry-powder formulation of treprostinil, for the treatment of PAH and PH-ILD. The approval is based on the INSPIRE trial, which demonstrated YUTREPIA's safety, tolerability, and efficacy.

  GlobeNewswire Inc.

  Featured Companies: UTHR
• Liquidia corp chief medical officer sells $18.4k in stock - Investing.com

  Liquidia Corp's Chief Medical Officer, Rajeev Saggar, has sold 1,470 shares of the company's common stock for $18,419, pursuant to a pre-scheduled 10b5-1 trading plan. The sale was to cover taxes associated with the vesting of restricted stock units.

  Investing.com
• Forecasting The Future: 5 Analyst Projections For Liquidia

  5 analysts have shared their evaluations of Liquidia (NASDAQ:LQDA) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $28.8, with a high estimate of $32.00 and a low estimate of $28.00. A decline of 1.81% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Liquidia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Serge Belanger Needham Maintains Buy $28.00 $28.00 Andrew Fein HC Wainwright & Co. Maintains Buy $32.00 $32.00 Serge Belanger Needham Maintains Buy $28.00 $28.00 Serge Belanger Needham Maintains Buy $28.00 - Serge Belanger Needham Maintains Buy $28.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Liquidia. This information provides a snapshot ...Full story available on Benzinga.com

  Benzinga
• MannKind Outperforms As Tyvaso DPI Captures Market Share

  MannKind's long-term liabilities exceed its assets, posing potential financial risks. Learn why MNKD stock is a Buy.

  Seeking Alpha

  Featured Companies: MNKD MRK UTHR
• Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)

  Liquidia Technologies (LQDA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  Zacks Investment Research